Foghorn Therapeutics (FHTX) announced that Kristian Humer will join the company as Chief Financial Officer on April 16, 2024 Humer joins Foghorn with over 14 years of diversified financial strategy and business development experience in the life science industry and more than 20 years of experience in the financial industry. Prior to joining Foghorn, Humer most recently held executive roles at Viridian Therapeutics (VRDN), where he successfully led financial strategy and business development as the Chief Financial Officer and Chief Business Officer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics Unveils Cancer Research Breakthroughs
- Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
- Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
- Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
- Foghorn Therapeutics Unveils New Investor Presentation